Cipher Pharmaceuticals (TSE:CPH) Stock Crosses Below 50-Day Moving Average – Here’s Why

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of C$17.72 and traded as low as C$16.00. Cipher Pharmaceuticals shares last traded at C$16.31, with a volume of 17,402 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group set a C$17.00 price target on Cipher Pharmaceuticals and gave the company a “hold” rating in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, Cipher Pharmaceuticals currently has an average rating of “Hold” and an average target price of C$17.00.

Cipher Pharmaceuticals Stock Performance

The company has a market capitalization of C$414.13 million, a PE ratio of 13.71 and a beta of 1.10. The company has a quick ratio of 2.67, a current ratio of 1.25 and a debt-to-equity ratio of 0.32. The company has a 50-day moving average price of C$17.72 and a two-hundred day moving average price of C$16.05.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its quarterly earnings results on Thursday, May 7th. The company reported C$0.33 earnings per share for the quarter. The company had revenue of C$17.39 million during the quarter. Cipher Pharmaceuticals had a return on equity of 25.69% and a net margin of 60.82%. Analysts predict that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.